| 查看: 1784 | 回复: 101 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
【转自药渡网】Teva 报告了乐观哮喘临床3期评估结果
|
|||
|
Teva 对临床3期评估了对于哮喘患者干粉吸入器 (MDPIs)吸入Fluticasone Propionate /Salmeterol和多剂量Fluticasone Propionate 的实验效果，实验数据很好。研究表明通过使用干粉吸入器 (MDPI)，低剂量与安慰剂相比具有更大的效能，结果展示 Teva 扩大呼吸的研发能力和支持其核心，呼吸驱动MDPI平台的发展。最初的结果显示fluticasone propionate/salmeterol MDPI的不良事件可以和fluticasone propionate治疗和安慰剂媲美。 相关阅读： Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo Results showcase Teva’s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes. “These data support Teva’s commitment to further optimize the treatment of respiratory disease through the development of devices and therapies that help address the needs of patients and physicians,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “With this dual development program we have demonstrated clinically significant levels of effectiveness, by delivering combination and monotherapy at lower doses utilizing our core, breath-actuated, MDPI platform.” Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV1 from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo. Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo. The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Full results will be submitted for presentation at future scientific meetings and for publication in peer reviewed journals. “We have made significant progress in furthering our respiratory pipeline with a focus on a complete asthma management system utilizing our breath-actuated MDPI platform,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We have successfully developed and launched products that utilize our breath-actuated MDPI platform in select markets around the world. These data support the broadening of our portfolio in using this technology to develop and deliver additional respiratory therapeutic options.” Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016. |
回复此楼» 猜你喜欢
材料学调剂
已经有9人回复
-
0856材料专业298分有科研经历 硕士研究生调剂自荐信
已经有5人回复
-
321求调剂一志愿东北林业大学材料与化工英二数二
已经有6人回复
-
调剂
已经有3人回复
-
290求调剂
已经有8人回复
-
材料类求调剂
已经有8人回复
-
材料284求调剂，一志愿郑州大学英一数二
已经有7人回复
-
求调剂
已经有5人回复
-
302材料工程求调剂
已经有4人回复
-
材料化工调剂
已经有6人回复
» 抢金币啦！回帖就可以得到:
-
单曲循环久了很多都会变
+1/396
-
上海交通大学叶天南课题组招聘2026级博士研究生
+1/79
-
山东理工大学材料学院泰山学者青年专家招收2026年调剂硕士研究生
+1/76
-
大理大学博士研究生招生
+1/62
-
西安工业大学庞教授课题组招收申请考核制 2026级学术博士生（电子/材料/物理/化学等）
+1/39
-
江西师范大学王昆-卢章辉课题组招化学方向研究生两名
+1/28
-
齐鲁工业大学（山东省科学院）济南 高校教师招聘 有机化学 事业编
+2/23
-
【加拿大卡尔顿大学】招博士生【心理学人工智能】
+1/15
-
you can see 26届计算机、电子信息类、电科考研T j信息pp骏：74+08+76+6+20/
+1/9
-
中国科学院国家级人才团队博士后招聘启示
+1/8
-
26届计算机、电子信息类、电科、控制、通信考研T j信息醇：10+33+77+47+03
+1/8
-
邀稿综述，作者排名和工作量分工问题，存在不满和疑问。
+1/6
-
中科院深圳先进技术研究院成会明院士/唐永炳杰青团队拟招聘博士后若干名。
+1/4
-
【研究生调剂招生】北京高校副校长团队招收机械类，环境类学硕和专硕
+1/4
-
济南大学耿兵氟化学课题组现招收2026级化学工程学硕专硕共4名
+1/3
-
武汉科技大学黄思煜教授招收博/硕士及师资博士后、特任教授
+1/2
-
招收2026级全日制博士生（学术学位/专业学位）--大连海事大学船舶与海洋工程学院
+1/2
-
新加坡南洋理工大学- 光电/ 智能传感/ 脑机接口方向 博士后
+1/1
-
深圳大学何传新课题组诚聘“百人计划”（副）教授、助理教授
+1/1
-
26届计算机、电子信息类、电科、控制、通信考研T j信息pp骏：74+08+76+6+20》
+1/1
83楼2015-11-20 16:21:10
简单回复
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
。 发自小木虫Android客户端
江南的竹10楼
2015-11-20 15:58
回复
药渡(金币+1): 谢谢参与
。 [ 发自小木虫客户端 ]
